HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare is supported by a leading competitive moat as the largest integrated healthcare delivery system in the U.S., with stable-to-improving positioning across 43 domestic markets, first- or second-place volume positions in many key markets, and an outpatient sites-per-hospital ratio that has risen from 12-to-1 in 2023 to over 14-to-1 currently versus a 20-to-1 target by the end of the decade. Its outlook is further reinforced by disciplined cost execution, including a $400m resiliency expectation in FY26 that may increase, a 2026 CapEx plan of $5.0–$5.5 billion, and EBITDA expected to move to $4.18b from $4.06b on stronger fourth-quarter cost reductions. The company also has ample balance-sheet capacity to fund buybacks, capex, and M&A while its outpatient expansion, clinical-digital integration, and payer-data initiatives should support continued growth at or above its long-term EBITDA target of +4-6% yty overtime.

HCA Healthcare is facing a weaker fundamental setup as same-store revenue growth is decelerating, with the August hospital revenue survey at +0.8% yty versus +2.7% in 2Q26, alongside softer surgical volumes, a deteriorating payor mix, and elevated charity care and bad debt. Management’s revised outlook appears insufficient to offset these pressures, since core EBITDA growth implied by the updated guidance falls to about 5.7% at the midpoint, below earlier expectations, while the analyst’s 2026 adjusted EBITDA estimate was cut to $15.75B from $16.0B. The stock also remains vulnerable to an estimated ~$1.3B HIX headwind, rising labor and supply costs, and reimbursement risk from government and managed care payors, all of which threaten margins and execution through 3Q-4Q26.